ArticleInvestigative ophthalmology & visual science2026
Protective Effect of Calcitonin Gene-Related Peptide on Corneal Epithelial Barrier in Experimental Dry Eye Models.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the role of calcitonin gene-related peptide (CGRP) in corneal epithelial barrier dysfunction in dry eye disease (DED). Methods: Benzalkonium chloride (BAC)-induced murine dry eye models and hyperosmotic-stressed human corneal epithelial cells-transformed (HCE-T) were used. Corneal nerve density and CGRP expression were assessed via whole-mount staining and Western blot. CGRP receptor components, including CRLR, RAMP-1, and CRCP, were evaluated by quantitative real-time PCR and immunofluorescence. Mice received a topical CGRP solution (50 µM) for four days. Barrier function was analyzed using Oregon Green Dextran (OGD) staining and transepithelial electrical resistance (TEER). Tight junction proteins, inflammatory markers, and PKA/CREB/NF-κB signaling pathways were examined via immunofluorescence, qPCR, and Western blot. Results: BAC exposure caused significant corneal nerve damage (P < 0.05) and a reduction of CGRP levels (P < 0.001), accompanied by upregulation of CGRP receptor components (CRLR, RAMP-1, CRCP; P < 0.05). Exogenous CGRP treatment restored corneal epithelial barrier function, as indicated by decreased OGD staining intensity (P < 0.001) and improved TEER (P < 0.001), while maintaining the localization of tight junction proteins. Mechanistically, CGRP increased p-PKACα (T197)/PKACα and p-CREB (S133)/CREB (P < 0.01), while reducing p-p65 and IL-1β, IL-6, TNF-α, MMP-9 (P < 0.01). These effects were observed in both BAC-induced DED mice and in hyperosmotic-stressed human corneal epithelial cells, demonstrating that CGRP exerts dual mechanisms in barrier repair and anti-inflammatory protection. Conclusions: CGRP deficiency and receptor upregulation may be involved in the pathological process of DED. Exogenous CGRP ameliorates corneal barrier dysfunction, which is associated with modulation of the PKA/CREB and NF-κB pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.